BCAX on Nasdaq
Bicara Therapeutics Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| General and administrative | $30.5M | $18.8M |
| Total operating expenses | $155.6M | $82.4M |
| Loss from operations | -$155.6M | -$82.4M |
| Interest income | $17.9M | $14.6M |
| Total other income, net | $17.9M | $14.6M |
| Net loss before income taxes | -$137.7M | -$67.8M |
| Income tax expense | -$217.0K | -$187.0K |
| Net loss | -$137.9M | -$68.0M |
| Net Loss per share, basic (in usd per share) | -$2.52 | -$4.05 |
| Net Loss per share, diluted (in usd per share) | -$2.52 | -$4.05 |
| Weighted-average number common shares outstanding, basic (in shares) | 54.7B shares | 16.8B shares |
| Weighted-average number common shares outstanding, diluted (in shares) | 54.7B shares | 16.8B shares |
| Unrealized gain on marketable securities, net of tax | $243.0K | $0 |
| Total other comprehensive income | $243.0K | $0 |
| Total comprehensive loss | -$137.7M | -$68.0M |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $96.7M | $489.7M | |
| Prepaid expenses and other assets | $7.3M | $12.8M | |
| Marketable securities | $318.1M | $0 | |
| Total current assets | $422.1M | $502.5M | |
| Property and equipment, net | $330.0K | $155.0K | |
| Right of use asset operating lease | $1.7M | $690.0K | |
| Other assets | $6.9M | $6.6M | |
| Total assets | $431.0M | $510.0M | |
| Operating lease liability current portion | $1.1M | $607.0K | |
| Total current liabilities | $28.9M | $18.0M | |
| Operating lease liability net of current portion | $593.0K | $131.0K | |
| Total liabilities | $29.5M | $18.1M | |
| Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | |
| Common stock, $0.0001 par value, 500,000,000 shares authorized; 56,600,724 and 54,444,180 shares issued and 56,600,724 and 54,440,013 shares outstanding as of December 31, 2025 and December 31, 2024, respectively | $7.0K | $7.0K | |
| Additional paid-in capital | $760.2M | $712.9M | |
| Accumulated other comprehensive gain | $243.0K | $0 | |
| Accumulated deficit | -$359.0M | -$221.0M | |
| Total stockholders' equity | $401.5M | $491.9M | -$148.8M |
| Total liabilities and stockholders equity | $431.0M | $510.0M | |
| Preferred stock, par value (in usd per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in usd per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | |
| Common stock, shares issued (in shares) | 56.6M shares | 54.4M shares | |
| Common stock, shares outstanding (in shares) | 56.6M shares | 54.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$137.9M | -$68.0M |
| Stock-based compensation | $15.0M | $7.4M |
| Depreciation | $105.0K | $56.0K |
| Non-cash lease expense | $895.0K | -$77.0K |
| Net amortization of premiums and discounts on marketable securities | $301.0K | $0 |
| Prepaid expenses and other assets | $5.3M | -$16.9M |
| Operating lease liabilities | -$932.0K | $81.0K |
| Net cash used in operating activities | -$106.8M | -$74.8M |
| Purchases of marketable securities | -$318.2M | $0 |
| Purchase of property and equipment | -$280.0K | -$71.0K |
| Proceeds from sale of property and equipment | $0 | $62.0K |
| Net cash used in investing activities | -$318.5M | -$9.0K |
| Proceeds from issuance on common stock, net of issuance costs | $29.5M | $332.4M |
| Proceeds from exercise of options | $2.8M | $1.6M |
| Net cash provided by financing activities | $32.3M | $334.0M |
| Net increase (decrease) in cash and cash equivalents | -$393.0M | $259.3M |
| Right-of-use asset obtained in exchange for lease liability | $1.9M | $413.0K |
Recent filings
- Oct 7, 2026SCHEDULE 13G/A
- Sep 10, 20264
- Sep 8, 2026144
- Sep 8, 2026144
- Aug 25, 20268-K
- Aug 14, 20263
- Aug 14, 20264
- Aug 13, 2026SCHEDULE 13G/A
- Aug 12, 20264
- Aug 12, 20264
- Aug 12, 20264
- Aug 11, 20268-K
- Aug 11, 202610-Q
- Aug 11, 2026S-8
- Aug 10, 2026144
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6